When should an alternative agent to vancomycin be considered for MRSA infections?

Update: 2010-11-21

Description

In this Episode, Dr. Scott T. Micek from Barnes-Jewish Hospital in St. Louis, Missouri provides insights
on when an alternative agent to vancomycin should be considered for MRSA infections.

Comments

In Channel

What are the short- and long-term challenges as well as advancements that will impact the management of patients with MRSA infections?

2011-02-1306:27

How can we prevent the spread of MRSA in the hospital?

2011-02-0607:59

Is there a role for OPAT in the management of patients with MRSA infections?

2011-01-3007:29

Can we determine the appropriate duration of therapy for MRSA infections?

2011-01-2309:43

What stewardship tactics can be applied to the management of MRSA infections?

2011-01-1609:31

Can we differentiate among newer agents for MRSA bacteremia and endocarditis?

2011-01-0909:57

How should clinicians manage MRSA bacteremia and infective endocarditis?

2011-01-0206:47

How can primary care physicians manage community-associated MRSA pneumonia?

2010-12-2606:23

What is the optimal treatment for MRSA nosocomial pneumonia?

2010-12-1907:50

What are the therapeutic options for a complicated skin or skin structure MRSA infection?

2010-12-1208:54

How can clinicians optimally manage community-associated MRSA skin infections?

2010-12-0507:53

What strategies can be used to effectively manage patients with skin and soft tissue MRSA infections?